Brief: Biophytis Enrolls First Patient In COVA On COVID-19 Related Respiratory Failure

Biophytis SA

01/09/2020 07:20

Sept 1 (Reuters) - BIOPHYTIS SA  ALBPS.PA :
    * ENROLLS FIRST PATIENT IN COVA, A MULTINATIONAL PHASE 2/3
CLINICAL TRIAL WITH SARCONEOS (BIO101) FOR THE TREATMENT OF
PATIENTS WITH COVID-19 RELATED RESPIRATORY FAILURE
    * FIRST PATIENT DOSED IN MECHELEN, BELGIUM
    * 5 CENTERS IN BELGIUM, FRANCE AND THE US ARE OPEN FOR
PATIENT
RECRUITMENT
    * IT IS DESIGNED TO EVALUATE EFFICACY AND SAFETY OF
SARCONEOS
(BIO101) AS A TREATMENT TO PREVENT FURTHER RESPIRATORY
DETERIORATION IN COVID-19 PATIENTS
    * THIS PIVOTAL CLINICAL TRIAL (NCT04472728) TAKING PLACE IN
BELGIUM, FRANCE, BRAZIL, THE UK AND US, WILL BE CONDUCTED IN TWO
PARTS
    * THE TRIAL EXPECTS TO RECRUIT A TOTAL OF ABOUT 310 PATIENTS
    * THE FIRST PART OF TRIAL HAS OBJECTIVE TO ASSESS TREATMENT
SAFETY
AND PROVIDE AN INDICATION OF ACTIVITY OF SARCONEOS (BIO101), IN
50 HOSPITALIZED PATIENTS
    * BIOPHYTIS SA - SECOND PART OF STUDY WILL INVESTIGATE
EFFICACY OF
SARCONEOS (BIO101) ON RESPIRATORY FUNCTION OF AN ADDITIONAL 260
COVID-19 PATIENTS
    * THE PRIMARY ENDPOINT IS THE PROPORTION OF ALL-CAUSE
MORTALITY
AND RESPIRATORY DETERIORATION WITHIN UP TO A 28-DAY PERIOD
    * THE FIRST PATIENT DOSED IS AN IMPORTANT MILESTONE FOR
MULTINATIONAL COVA STUDY WHICH IS NOW RECRUITING AT FIVE CENTERS
IN FRANCE, BELGIUM AND THE US-CEO

Source text: https://bit.ly/3lAXUpl
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))